News

The FDA is asking Novavax for a non-mandatory postmarketing commitment to produce additional clinical data for its ...
The FDA is considering the approval of the Novavax COVID-19 booster after delays amid controversy over its non-mRNA design.
Novavax’s protein-based vaccine is only available under a pandemic-era emergency-use authorization, and formal approval from ...